Recent Policy Updates

After review by Committee on Research; changes approved by VPDOR, President&Provost for updates to composition of ICOIC (section 5.D.)

Approved by leadership of Office of Technology Licensing. Added to Section 3.A 3 2) that clinical trial research ends at Stanford, and or when the license is terminated, or the product which was the subject of the clinical trial is no longer being developed by a licensee/sublicensee.

In developing this policy and related procedures, the University has taken into account the issues identified and discussed in "Protecting Patients, Preserving Integrity, Advancing Health: Accelerating Implementation of COI Policies in Human Subjects Research," published in 2008 by the Association of American Medical Colleges (AAMC) and the Association of American Universities (AAU).

Establishes principles and procedures designed to ensure that research involving human subjects at Stanford University is conducted without untoward influence resulting from either the University's financial investments or holdings or the personal financial interests or holdings of key institutional leaders.